跳轉至內容
Merck
全部照片(1)

重要文件

1508901

USP

己酮可可碱

United States Pharmacopeia (USP) Reference Standard

同義詞:

3,7-Dimethyl-1-(5-oxohexyl)xanthine, Trental

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C13H18N4O3
CAS號碼:
分子量::
278.31
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

pentoxifylline

製造商/商標名

USP

應用

pharmaceutical (small molecule)

形式

neat

SMILES 字串

CN1C=NC2C1C(=O)N(CCCCC(C)=O)C(=O)N2C

InChI

1S/C13H20N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8,10-11H,4-7H2,1-3H3

InChI 密鑰

MQGNNJQTNFHNHK-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Pentoxifylline USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Pentoxifylline Compounded Oral Suspension
  • Pentoxifylline Extended-Release Tablets

生化/生理作用

Phosphodiesterase inhibitor; inhibits synthesis of tumor necrosis factor α (TNF-α).

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral - Lact.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Shirinsadat Badri et al.
Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 14(1), 128-137 (2011-04-20)
Chronic kidney disease (CKD) as a considerable health problem may have proteinuria as the main complication and strong risk factor to reach end-stage renal disease (ESRD). Decreasing proteinuria is the mainstay of therapy in order to delay the progression of
R Parker et al.
Alimentary pharmacology & therapeutics, 37(9), 845-854 (2013-03-16)
Acute alcoholic hepatitis (AH) is a severe manifestation of alcoholic liver disease with a grave prognosis. Pentoxifylline, an oral antitumour necrosis factor agent, has been reported to reduce mortality and incidence of hepatorenal syndrome (HRS) in severe alcoholic hepatitis (SAH).
Simone Appenzeller et al.
Rheumatology international, 31(11), 1511-1513 (2009-12-17)
Behcet's disease is an inflammatory disorder of unknown cause, characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesions. All these common manifestations are self-limiting except for the ocular attacks. The objective of the present study is to
Emma Harris et al.
Paediatric drugs, 12(5), 301-311 (2010-08-31)
Sepsis, necrotizing enterocolitis (NEC), and chronic lung disease (CLD) in preterm neonates are associated with significant mortality and morbidity, including long-term neurodevelopmental impairment and socioeconomic burden. Safe and effective drugs for the prevention and treatment of these conditions are urgently
Khalid N Haque et al.
The Cochrane database of systematic reviews, (10)(10), CD004205-CD004205 (2011-10-07)
Mortality and morbidity due to neonatal sepsis and necrotizing enterocolitis (NEC) is high despite the use of potent antimicrobial agents. Agents that modulate inflammation may improve outcomes. Pentoxifylline, a phosphodiesterase inhibitor, is one such agent. The primary objectives were to

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務